American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

01 June 2018 - 05 June 2018

High-dose esomeprazole plus aspirin can help prevent oesophageal carcinoma

Dr. Joseph Delano Fule Robles, 20180621015034

High-dose esomeprazole in combination with aspirin can moderately reduce the risk of developing high-grade dysplasia or oesophageal cancer or delay death from any cause in patients with Barrett’s oesophagus (BE).

Taselisib plus fulvestrant shows encouraging results for advanced breast cancer

Dr. Joseph Delano Fule Robles, 20180621014138

The selective PI3K inhibitor taselisib in combination with fulvestrant has demonstrated efficacy in patients with oestrogen receptor (ER)-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.

$Once-weekly carfilzomib promising in relapsed/refractory multiple myeloma$

Once-weekly carfilzomib promising in relapsed/refractory multiple myeloma

Christina Lau, 20180620105634

Once-week carfilzomib may represent a more convenient treatment option for patients with relapsed/refractory multiple myeloma (R/R MM), according to data from the phase III ARROW trial.

ARCHER 1050: Dacomitinib shows superior OS vs gefitinib in first-line EGFR-positive NSCLC

Jackey Suen, 20180620100835

The EGFR tyrosine kinase inhibitor (TKI) dacomitinib showed superior overall survival (OS) vs gefitinib in patients with treatment-naïve EGFR-positive non-small-cell lung cancer (NSCLC) in the final analysis of the ARCHER 1050 study.

Adjuvant mFOLFIRINOX extends OS by almost 20 months in pancreatic cancer

Christina Lau, 20180619070739

Adjuvant treatment with a modified FOLFIRINOX (mFOLFIRINOX) regimen extends overall survival (OS) by nearly 20 months compared with standard chemotherapy in patients with nonmetastatic pancreatic ductal adenocarcinoma (PDAC), results of a phase III trial have shown.

TAILORx: Gene expression assay helps spare adjuvant chemo in many breast cancer patients

Christina Lau, 20180612094424

Clinical use of a 21-gene expression assay can help spare adjuvant chemotherapy in many patients with early breast cancer, according to results of a large trial hailed by experts as practice-changing.

KEYNOTE: Most patients with advanced NSCLC can start treatment without chemo

Christina Lau, 20180612072234

Most patients with advanced non-small-cell lung cancer (NSCLC) can have improved overall survival (OS) with first-line pembrolizumab without chemotherapy even if their PD-L1 expression levels are low, results of the phase III KEYNOTE-042 trial have shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.